In that study, rates of persistence (continuation of the index therapy) at 180 days were 46.8%73.5% among patients taking exenatide twice daily, 50.6%80.1% with liraglutide once daily, and 57.5%74.6% with exenatide once weekly
With advancing age, carnitine levels decline in all our tissues
Survodutide is a candidate drug in the obesity treatment pipeline, belonging to a class of dual GLP-1 and GCGR agonists
Your dose may need to go up as you progress through titration, but your price remains stable, making long-term treatment predictable and budget-friendly
The IC measures the disproportionality of specific combinations of drugs and adverse events compared to all other combination trends in the database
What's Included in This Combo Offer